259 related articles for article (PubMed ID: 25435371)
1. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.
Mapelli P; Aboagye EO; Stebbing J; Sharma R
Oncogene; 2015 Aug; 34(34):4439-47. PubMed ID: 25435371
[TBL] [Abstract][Full Text] [Related]
2. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tumours: cracking the epigenetic code.
Karpathakis A; Dibra H; Thirlwell C
Endocr Relat Cancer; 2013 Jun; 20(3):R65-82. PubMed ID: 23429748
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic aspects on therapy development for gastroenteropancreatic neuroendocrine tumors.
Larsson C
Neuroendocrinology; 2013; 97(1):19-25. PubMed ID: 22456267
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
[TBL] [Abstract][Full Text] [Related]
7. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system.
Arnold CN; Sosnowski A; Schmitt-Gräff A; Arnold R; Blum HE
Int J Cancer; 2007 May; 120(10):2157-64. PubMed ID: 17278096
[TBL] [Abstract][Full Text] [Related]
8. Analysis of molecular pathways in neuroendocrine cancers of the gastroenteropancreatic system.
Arnold CN; Sosnowski A; Blum HE
Ann N Y Acad Sci; 2004 Apr; 1014():218-9. PubMed ID: 15153437
[TBL] [Abstract][Full Text] [Related]
9. Deregulated chromatin remodeling in the pathobiology of brain tumors.
Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.
How-Kit A; Dejeux E; Dousset B; Renault V; Baudry M; Terris B; Tost J
Epigenomics; 2015; 7(8):1245-58. PubMed ID: 26360914
[TBL] [Abstract][Full Text] [Related]
11. Gastroenteropancreatic endocrine tumors.
Meeker A; Heaphy C
Mol Cell Endocrinol; 2014 Apr; 386(1-2):101-20. PubMed ID: 23906538
[TBL] [Abstract][Full Text] [Related]
12. Implication of the INK4a/ARF locus in gastroenteropancreatic neuroendocrine tumorigenesis.
Simon B; Lubomierski N
Ann N Y Acad Sci; 2004 Apr; 1014():284-99. PubMed ID: 15153447
[TBL] [Abstract][Full Text] [Related]
13. Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours.
Stricker I; Tzivras D; Nambiar S; Wulf J; Liffers ST; Vogt M; Verdoodt B; Tannapfel A; Mirmohammadsadegh A
Anticancer Res; 2012 Sep; 32(9):3699-706. PubMed ID: 22993308
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter.
Wu LP; Wang X; Li L; Zhao Y; Lu S; Yu Y; Zhou W; Liu X; Yang J; Zheng Z; Zhang H; Feng J; Yang Y; Wang H; Zhu WG
Mol Cell Biol; 2008 May; 28(10):3219-35. PubMed ID: 18332107
[TBL] [Abstract][Full Text] [Related]
15. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors.
Gilbert JA; Lloyd RV; Ames MM
N Engl J Med; 2005 Jul; 353(2):209-10. PubMed ID: 16014895
[No Abstract] [Full Text] [Related]
16. Molecular genetics of gastroenteropancreatic neuroendocrine tumors.
Starker LF; Carling T
Curr Opin Oncol; 2009 Jan; 21(1):29-33. PubMed ID: 19125015
[TBL] [Abstract][Full Text] [Related]
17. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Cancer Treat Rev; 2015 May; 41(5):423-30. PubMed ID: 25837868
[TBL] [Abstract][Full Text] [Related]
18. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors.
Rahman MM; Qian ZR; Wang EL; Yoshimoto K; Nakasono M; Sultana R; Yoshida T; Hayashi T; Haba R; Ishida M; Okabe H; Sano T
Hum Pathol; 2010 Aug; 41(8):1069-78. PubMed ID: 20381114
[TBL] [Abstract][Full Text] [Related]
19. NETs: organ-related epigenetic derangements and potential clinical applications.
Cives M; Simone V; Rizzo FM; Silvestris F
Oncotarget; 2016 Aug; 7(35):57414-57429. PubMed ID: 27418145
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter CpG methylation and its translational applications in breast cancer.
Xiang TX; Yuan Y; Li LL; Wang ZH; Dan LY; Chen Y; Ren GS; Tao Q
Chin J Cancer; 2013 Jan; 32(1):12-20. PubMed ID: 22059908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
